Ercilia Arias, MD
Pulmonary Disease · Lewes, DENPI 1720032675
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.4%), education and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Intuitive Surgical at 43.9% of the total. Reporting peaked in 2024 at $5,663 and has fallen 62.4% since, to $2,129 in 2025.
Across 190 payments — averaging $57.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- AstraZeneca$998
- GSK$919
- Boehringer Ingelheim$676
- Mallinckrodt Hospital Products Inc.$349
- United Therapeutics Corporation$306
- plus $3K from 32 others
What the payments were for
- Travel & lodging$8177%
- Food & beverage$5,96154%
- Education$4,18638%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $4,817 |
| AstraZeneca | 23 | $998 |
| GSK | 32 | $919 |
| Boehringer Ingelheim | 18 | $676 |
| Mallinckrodt Hospital Products Inc. | 13 | $349 |
| United Therapeutics Corporation | 7 | $306 |
| Harmony Biosciences LLC | 7 | $293 |
| Sanofi | 12 | $260 |
| Jazz Pharmaceuticals Inc. | 4 | $254 |
| Sanofi-aventis U.S. LLC | 2 | $179 |
| Grifols USA, LLC | 7 | $155 |
| Merck | 2 | $149 |
| Lilly USA, LLC | 3 | $144 |
| AbbVie | 7 | $144 |
| Penumbra, Inc. | 1 | $141 |
| Abiomed | 2 | $140 |
| Verona Pharma, Inc. | 7 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $114 |
| Nuwellis, Inc. | 1 | $110 |
| Boston Scientific | 1 | $87 |
| Sunovion Pharmaceuticals Inc. | 4 | $69 |
| Insmed, Inc. | 4 | $69 |
| Bayer | 3 | $67 |
| Regeneron Healthcare Solutions, Inc. | 1 | $57 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Resmed Corp | 2 | $36 |
| Astellas Pharma US Inc | 1 | $32 |
| Electromed, Inc. | 2 | $28 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $25 |
| Mylan Specialty L.p. | 1 | $24 |
| Viatris Specialty LLC | 1 | $23 |
| Viiv Healthcare Company | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,792
- OFEV$248
- BREZTRI$248
- SUNOSI$211
- TYVASO$157
- Indigo System$141
- WINREVAIR$125
- AIRSUPRA$125
- NUCALA$125
- TRELEGY ELLIPTA$123
- TEZSPIRE$122
- Impella$115
- Aquadex$110
- FASENRA$105
How this compares
$10,964 in reported general payments places this provider in the 80th percentile of 39 pulmonary disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 62 | $964,395 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 644 | $701,756 |
| WakixPitolisant Hcl | 12 | $195,524 |
| Pirfenidone | 36 | $187,313 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 161 | $124,906 |
| Dupixent PenDupilumab | 17 | $106,127 |
| Spiriva RespimatTiotropium Bromide | 89 | $84,274 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $65,827 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $59,592 |
| Incruse ElliptaUmeclidinium Bromide | 80 | $46,879 |
| Arnuity ElliptaFluticasone Furoate | 97 | $39,423 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $19,893 |
| Spiriva HandihalerTiotropium Bromide | 26 | $13,508 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 337 | $11,288 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $10,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $676 | $1,055,586162 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $919 | $978,7911,058 claims |
| Harmony Biosciences LLCWakix | $293 | $195,52412 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $998 | $79,485119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 39 pulmonary disease providers in Delaware.
Other pulmonary disease in Lewes
- Victor BanzonLewes$300K
- Vikas BatraLewes$17K
- Samih RaadLewes$9K
- Omar MahmoudLewes$2K
- Albert RizzoNewark$162K
- Michel SamahaMilford$94K
- Haroon RajaNewark$44K
- Ismael MatusNewark$27K
- David JawaharDover$9K
- Anthony VasileWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.